Vitamin D is a lipid-soluble hormone found in certain foods and synthesized from precursors in the skin when exposed to ultraviolet light. Vitamin D plays a critical role in bone metabolism and many cellular and immunological processes and low levels have been associated with several chronic and infectious diseases. Vitamin D status is assessed by measuring the concentration of serum 25-hydroxyvitamin D [25(OH)D]. Vitamin D deficiency is reported to be common worldwide, but little has been reported about the vitamin D status of adults in Turkey. In this cross-sectional study, we determined the prevalence of 25(OH)D deficiency in adults residing in a city in the Aegean region of Turkey.
8 March 2019 in The Journal of Clinical Endocrinology & Metabolism
Context Dopamine agonist (DA)-induced impulse control disorder (ICD) in prolactinomas is not sufficiently known. Objective To evaluate the prevalence of DA-induced ICDs and possible risk factors related to these disorders in patients with prolactinoma. Design, Setting and Participants This is a cross-sectional multicenter study involving 308 prolactinoma patients followed-up in tertiary referral centers who received at least 3 months of DA therapy. DA-induced ICDs (pathological gambling, hypersexuality, compulsive shopping and compulsive eating) and impulsivity were assessed using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP) and the Barratt Impulsiveness Scale-11 (BIS-11), respectively. Patients were evaluated in terms of parameters related with ICD development. Results Any ICD prevalence was 17% (n=51). Most common type was hypersexuality (6.5%). While any ICD and hypersexuality were more common in male patients (p=0.009, p<0.001, respectively), compulsive eating was more common in female patients (p=0.046). Current smoking, alcohol use and gambling history were more frequent (p=0.033, p=0.002, p=0.008, respectively) in patients with any ICD. In BIS-11 total, attentional, motor and non-planning scores were significantly higher in patients with any ICD (p<0.001). Current smoking and alcohol use were more frequent (p=0.007, p=0.003, respectively) and percentage increase of testosterone levels at last visit was higher (p=0.021) in male prolactinomas with hypersexuality. Conclusion Any ICD may be seen in one out of six with prolactinoma patients who are receiving DA therapy and endocrinology specialists should be aware of this significant side effect particularly in male patients with a history of gambling, smoking or alcohol use.
The aims of this prospective study were to determine serum levels of creatine kinase (CK) in overt and subclinical hypothyroidism; to investigate the change in CK levels with treatment; and to evaluate the relationship between free triiodsothyronine (FT3), free thyroxine (FT4), and thyrotropin (TSH) levels and the degree of skeletal muscle involvement, as determined by serum CK levels. Patients with hypothyroidism presenting to our endocrinology clinic were eligible for inclusion in this study. Patients with other causes of CK elevation were excluded. We included 28 patients (25 women and 3 men, ages 41.75 ± 13.65 years) with overt hypothyroidism, 38 patients (37 women, 1 man, ages 40.55 ± 10.48 years) with subclinical hypothyroidism, and 30 age- and gender-matched controls (27 women, 3 men, ages 40.81 ± 11.20 years) in the study. Serum levels of TSH, FT4, FT3, and CK were measured in all subjects. CK elevation was found in 16 patients (57%) with overt hypothyroidism and in 4 patients (10%) with subclinical hypothyroidism. Although a statistically significant elevation of CK levels was found in patients with overt hypothyroidism when compared with patients with subclinical hypothyroidism and controls (p = 0.0001, p = 0.01, respectively), no difference was found between the subclinical hypothyroidism and control groups (p = 0.14). In hypothyroid (overt and subclinical) patients, a positive correlation was found between CK and TSH (r = 0.432; p = 0.04), and a negative correlation between CK and FT3 (r = −0.556; p = 0.002) and between CK and FT4 (r = −0.448; p = 0.04). CK levels decreased to normal levels after thyroid function normalized with treatment. In conclusion, skeletal muscle is affected by hypothyroidism more profoundly in cases of overt hypothyroidism, less so when subclinical hypothyroidism is present.
The aims of this study were to: 1) determine the prevalence of hyperprolactinaemia in patients with newly diagnosed subclinical and overt hypothyroidism, and 2) investigate the change in PRL levels with treatment. In this observational study, patients with a new diagnosis of hypothyroidism in our endocrinology clinic were approached for participation, as were healthy controls. Patients with medical reasons for having elevated PRL levels, lactating and pregnant women were excluded from the study. No patient had kidney or liver disease. After examination to determine if clinical causes of PRL elevation were present, serum levels of thyrotropin (TSH), free thyroxine, free triiodothyronine and PRL were measured and correlation of PRL levels with the severity of hypothyroidism (overt or subclinical) was performed. Fifty-three patients (45 women, 8 men, mean age 45.3 ± 12.2 years) had overt hypothyroidism. One hundred forty-seven patients (131 women, 16 men, mean age 42.9 ± 12.6 years) had subclinical hypothyroidism. One hundred healthy persons (85 women, 15 men, mean age 43.9 ± 11.4 years) participated as controls. The same blood tests were repeated in patients after normalization of TSH levels with L-thyroxine treatment. PRL elevation was found in 36% of patients with overt hypothyroidism, and in 22% of patients with subclinical hypothyroidism. PRL levels decreased to normal in all patients after thyroid functions normalized with L-thyroxine treatment. In the hypothyroid patients (overt and subclinical) a positive correlation was found between TSH and PRL levels (r=0.208, p=0.003). PRL regulation is altered in overt and subclinical hypothyroidism, and PRL levels normalize with appropriate L-thyroxine treatment.
6 November 2003 in Diabetes, Obesity and Metabolism